A quick post today:
News came out last week that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of the CAR-T treatment Liso-cel (also known as Breyanzi) for treatment of patients with Relapsed or Refractory Follicular Lymphoma who have already received two or more treatments.
This is great news. It potentially expands treatment options for R/R FL patients. The European Commission will review the recommendation and make a decision (it usually decides within two months). If it is approved, the CAR-T treatment will be available to patients with the European Union, as well as the European Economic Area countries Iceland, Norway and Liechtenstein.
Liso-cel has already been approved in the EU for a few types of lymphoma, including R/R Diffuse Large B Cell Lymphoma , high grade B Cell Lymphoma, and Grade 3B Follicular Lymphoma. This approval would greatly expand the number of patients who could receive the treatment.
I'll keep an eye on the news of the final approval when it happens.
1 comment:
Wohooo! I love knowing that there will be a lot of options down the line if I need them.
I was sad to hear of your skin cancer recent diagnosis, but I'm glad that you're not worried about it and that you were proactive about it. I was wondering about your biannual visit to the hematologist, since the previous ones were around these dates, and it would be the first one that I read "fresh" since I started reading the blog two months ago.
I hope you had an excellent January!
Fer
Fer
Post a Comment